Mycophenolate Export Market Intelligence: India's 167 Suppliers Shipping to 100 Countries — TransData Nexus 2026

Q: Who are the top mycophenolate exporters from India?

The top mycophenolate exporters from India are: 1. INTAS PHARMACEUTICALS LIMITED — $206.5M (61.7% market share); 2. STRIDES PHARMA SCIENCE LIMITED — $35.0M (10.5% market share); 3. ALKEM LABORATORIES LIMITED — $29.3M (8.8% market share); 4. SANDOZ PRIVATE LIMITED — $26.5M (7.9% market share); 5. EMCURE PHARMACEUTICALS LIMITED — $14.0M (4.2% market share). Together they account for 93.1% of India's total mycophenolate export value.

Q: What is the total export value of mycophenolate from India?

The total export value of mycophenolate from India is $334.4M USD, recorded across 2,529 shipment transactions from 167 active exporters to 100 destination countries. The average shipment value is $132.2K.

Q: Which countries import mycophenolate from India?

India exports mycophenolate to 100 countries worldwide. The top importing countries are: UNITED STATES (76.6% share, $256.2M), AUSTRALIA (6.1% share, $20.5M), UNITED KINGDOM (3.9% share, $13.0M), ITALY (1.3% share, $4.4M), BRAZIL (1.2% share, $4.1M). These five markets account for 89.2% of total export value.

Q: What is the average price of mycophenolate exports from India?

The average unit price for mycophenolate exports from India is $15.03 USD per unit, with prices ranging from $0.00 to $400.57 depending on formulation, packaging, and order volume. The total market is valued at $334.4M across 2,529 shipments.

Q: Which ports handle mycophenolate exports from India?

The primary ports for mycophenolate exports from India are SAHAR AIR (18.3% of shipments), NHAVA SHEVA SEA (INNSA1) (12.2% of shipments), SAHAR AIR CARGO ACC (INBOM4) (9.1% of shipments), JNPT/ NHAVA SHEVA SEA (5.3% of shipments), DELHI AIR (4.5% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of mycophenolate?

India is one of the world's leading exporters of mycophenolate due to its large base of 167 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports mycophenolate to 100 countries, demonstrating 51% global market coverage.

Q: What certifications do Indian mycophenolate exporters need?

Indian mycophenolate exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import mycophenolate from India?

There are 512 registered buyers importing mycophenolate from India, spread across 100 countries. The repeat buyer rate is 53.7%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top mycophenolate supplier from India?

INTAS PHARMACEUTICALS LIMITED is the leading mycophenolate exporter from India with a market share of 61.7% and total export value of $206.5M across 454 shipments. The top 5 suppliers together control 93.1% of total export value.

Suresh Sormare

Mycophenolate

India Pharmaceutical Trade Intelligence

$334.4M167 Suppliers100 CountriesHS 30049099

ExportsIndia → UNITED STATES76.6%India → AUSTRALIA6.1%

ImportsGERMANY → India$999.6M ITALY → India$223.6M

#1 Supplier: INTAS PHARMACEUTICALS #1 Buyer: EVERSANA LIFE

Mycophenolate Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Mycophenolate to the World

Between 2022 and 2026, India exported $334.4M worth of mycophenolate across 2,529 verified shipments to 100 countries — covering 51% of world markets in the Immunosuppressants segment. The largest destination is UNITED STATES (76.6%). INTAS PHARMACEUTICALS LIMITED leads with a 61.7% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published May 2026·Updated May 2026·

Mycophenolate export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Mycophenolate export data snapshot — $334.4M · 167 exporters · 100 countriesTransData Nexus · Indian Customs Data

Top Mycophenolate Exporters from India

167 active exporters · Ranked by export value

View all 167 →

Top Mycophenolate Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	INTAS PHARMACEUTICALS LIMITED	$206.5M	454	24	61.7%
2	STRIDES PHARMA SCIENCE LIMITED

Top Countries Importing Mycophenolate from India

100 destination markets · Ranked by import value

All 100 countries →

Top Countries Importing Mycophenolate from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	UNITED STATES	$256.2M	76.6%
2	AUSTRALIA	$20.5M	6.1%
3	UNITED KINGDOM	$13.0M	3.9%
4	ITALY	$4.4M	1.3%
5	BRAZIL	$4.1M	1.2%
6	CANADA	$4.0M	1.2%
7	GERMANY	$3.7M	1.1%
8	HONG KONG	$3.5M	1.1%
9	THAILAND	$3.2M	1.0%
10	ECUADOR	$2.6M	0.8%

UNITED STATES is India's largest mycophenolate export destination, absorbing 76.6% of total exports worth $256.2M. The top 5 importing countries — UNITED STATES, AUSTRALIA, UNITED KINGDOM, ITALY, BRAZIL — together account for 89.2% of India's total mycophenolate export value. The remaining 95 destination countries collectively receive the other 10.8%, indicating a well-diversified global distribution network spanning all major continents.

Who Supplies Mycophenolate to India?

17 origin countries · Total import value: $1.2B

India imports mycophenolate from 17 countries with a combined import value of $1.2B. The largest supplier is GERMANY ($999.6M, 27 shipments), followed by ITALY and SWITZERLAND. All values are from Indian Customs (DGFT) import records.

Countries Supplying Mycophenolate to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	GERMANY	$999.6M	27	81.6%
2	ITALY	$223.6M	31	18.3%
3	SWITZERLAND	$1.3M	5	0.1%
4	AUSTRIA	$279.7K	1	0.0%
5	UNITED STATES	$217.2K	23	0.0%
6	CANADA	$190.2K	18	0.0%
7	AUSTRALIA	$4.2K	5	0.0%
8	SLOVENIA	$4.1K	1	0.0%
9	ISRAEL	$2.9K	9	0.0%
10	UNITED KINGDOM	$2.4K	6	0.0%

Showing top 10 of 17 origin countries

GERMANY is the largest supplier of mycophenolate to India, accounting for 81.6% of total import value. The top 5 origin countries — GERMANY, ITALY, SWITZERLAND, AUSTRIA, UNITED STATES — together supply 100.0% of India's mycophenolate imports. Click any country to see detailed supplier and buyer data for that import corridor.

Mycophenolate — Export Intelligence Video

Visual overview of India's mycophenolate import and export market — top suppliers, destinations, pricing, and trade routes

This video covers India's mycophenolate pharmaceutical import and export market — $334.4M in total trade, 167 verified manufacturers, and 100 destination countries. Data sourced from Indian Customs (DGFT) shipment records.

Regulatory Landscape — Mycophenolate

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, mycophenolate is approved for preventing organ rejection in transplant patients. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for mycophenolate mofetil, indicating a competitive generic market. Notably, the reference product, CellCept (mycophenolate mofetil), received FDA approval on July 28, 2000. The substantial export volume from India to the U.S. underscores the importance of compliance with FDA regulations, including adherence to Current Good Manufacturing Practices (cGMP) and successful completion of the ANDA process. The presence of 167 active Indian exporters highlights the competitive landscape and the necessity for stringent quality control to maintain market access.

2EU & UK Regulatory Framework

In the European Union, mycophenolate-containing products, such as CellCept, have been authorized by the European Medicines Agency (EMA) since February 14, 1996. (ema.europa.eu) Generic versions, including Mycophenolate mofetil Teva, received EMA approval on February 21, 2008. (ema.europa.eu) The United Kingdom, following its departure from the EU, continues to regulate medicinal products through the Medicines and Healthcare products Regulatory Agency (MHRA). Both EMA and MHRA require compliance with Good Manufacturing Practice (GMP) standards, necessitating regular inspections and certifications for manufacturing facilities.

3WHO Essential Medicines & Global Standards

Mycophenolate mofetil is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in global health. The drug is subject to international pharmacopoeial standards, including those of the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality and efficacy across markets.

4India Regulatory Classification

In India, mycophenolate mofetil is classified as a Schedule H drug under the Drugs and Cosmetics Act, requiring a prescription for dispensation. The National Pharmaceutical Pricing Authority (NPPA) oversees the pricing of essential medicines; however, as of the latest updates, mycophenolate mofetil is not listed under the Drug Price Control Order (DPCO), allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with international trade regulations.

5Patent & Exclusivity Status

The primary patents for mycophenolate mofetil have expired, facilitating the entry of generic formulations into the market. This has led to increased competition among manufacturers, including Indian exporters, contributing to the widespread availability and affordability of the drug globally.

6Recent Industry Developments

In April 2024, the EMA approved a variation for Mycophenolate mofetil Teva, reflecting ongoing regulatory oversight and commitment to product quality. (ema.europa.eu) Additionally, in February 2025, the EMA updated the product information for Advagraf, another immunosuppressant, highlighting the dynamic nature of regulatory requirements in this therapeutic area. (ema.europa.eu) These developments underscore the importance for Indian exporters to stay abreast of regulatory changes to maintain compliance and market access.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Mycophenolate

Retail & reference prices across 9 markets vs. India FOB export price of $15.03/unit

Global Price Benchmark for Mycophenolate across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$2.50	USD	According to the FDA's Orange Book, Mycophenolate is an approved generic drug, contributing to its competitive pricing in the U.S. market.
United Kingdom	$2.35	GBP	The NHS Drug Tariff lists Mycophenolate, ensuring standardized pricing across the UK.
Germany	$2.20	EUR	The Federal Institute for Drugs and Medical Devices (BfArM) regulates pharmaceutical pricing, maintaining affordability for essential medications.
Australia	$2.10

Supply Chain Risk Assessment — Mycophenolate

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry, including the production of mycophenolate, heavily relies on China for Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). Approximately 70% of India's APIs are imported from China, underscoring a significant supply chain vulnerability. This dependency is particularly critical for KSMs, as China controls 70–80% of the global KSM supply, making it a strategic chokepoint in the pharmaceutical supply chain.

Recent disruptions have highlighted the risks associated with this reliance. For instance, in July 2018, environmental regulations led to the shutdown of several Chinese chemical plants, causing a surge in KSM prices and subsequent increases in API costs. Such events underscore the fragility of the supply chain and the potential for significant impacts on drug availability and pricing.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates a high concentration among Indian exporters of mycophenolate, with the top five suppliers accounting for 93.1% of total exports. INTAS PHARMACEUTICALS LIMITED alone holds a 61.7% share, exporting $206.5 million worth of mycophenolate. This concentration poses a significant single-source risk, as any disruption affecting these key suppliers could severely impact global supply chains.

To mitigate such risks, the Indian government launched the Production Linked Incentive (PLI) scheme in 2021, aiming to boost domestic manufacturing of critical KSMs and APIs. By September 2025, the scheme had attracted investments of ₹4,763.34 crore, surpassing the initial commitment of ₹4,329.95 crore over six years. While this initiative shows promise, its impact on reducing supplier concentration in the mycophenolate market remains to be fully realized.

Access Complete Mycophenolate Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 2,529 transactions across 100 markets.

Request Demo View Pricing

Frequently Asked Questions — Mycophenolate Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top mycophenolate exporters from India?

The leading mycophenolate exporters from India are INTAS PHARMACEUTICALS LIMITED, STRIDES PHARMA SCIENCE LIMITED, ALKEM LABORATORIES LIMITED, and 11 others. INTAS PHARMACEUTICALS LIMITED leads with 61.7% market share ($206.5M). The top 5 suppliers together control 93.1% of total export value.

What is the total export value of mycophenolate from India?

The total export value of mycophenolate from India is $334.4M, recorded across 2,529 shipments from 167 active exporters to 100 countries. The average shipment value is $132.2K.

Which countries import mycophenolate from India?

India exports mycophenolate to 100 countries. The top importing countries are UNITED STATES (76.6%), AUSTRALIA (6.1%), UNITED KINGDOM (3.9%), ITALY (1.3%), BRAZIL (1.2%), which together account for 89.2% of total export value.

What is the HS code for mycophenolate exports from India?

The primary HS code for mycophenolate exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Mycophenolate

Mycophenolate

Top Mycophenolate Exporters from India

Top Countries Importing Mycophenolate from India

Who Supplies Mycophenolate to India?

Quick Facts

Related Immunosuppressants

Related Analysis

Need Details?

Mycophenolate — Export Intelligence Video

Regulatory Landscape — Mycophenolate

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Mycophenolate

Supply Chain Risk Assessment — Mycophenolate

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Mycophenolate Trade Intelligence

Frequently Asked Questions — Mycophenolate Exports from India

Who are the top mycophenolate exporters from India?

What is the total export value of mycophenolate from India?

Which countries import mycophenolate from India?

What is the HS code for mycophenolate exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of mycophenolate exports from India?

Which ports handle mycophenolate exports from India?

Why is India a leading exporter of mycophenolate?

What certifications do Indian mycophenolate exporters need?

How many buyers import mycophenolate from India?

What is the market share of the top mycophenolate exporter from India?

Analysis Methodology